PMON208 metformin, spironolactone and oral contraceptives in polycystic ovary syndrome: a network meta-analysis
Abstract
Abstract Background Polycystic ovary syndrome (PCOS) is a complex endocrine disease with awide-spectrum of clinical presentations. For this reason, several therapeutic interventions have been proposed. Metformin, spironolactone and oral contraceptives (OC), alone or in combination, have demonstrated benefit, however, their results are heterogeneous across the evidence. Although several meta-analyses have evaluated these interventions, none has studied the combination between them nor focused on patient-important outcomes. Objective The primary aim of this study was to assess the effect of metformin, spironolactone and OC on testosterone levels. Other outcomes of interest were body mass index (BMI), metabolic profile (glucose, insulin, triglycerides and cholesterol), hormonal measures (LH, FSH, SHBG), and patient-important outcomes comprising hirsutism (measured with the Ferriman-Gallwey score), emotional well-being and quality of life. Methods A comprehensive search was conducted in MEDLINE, EMBASE, Web of Science, and Scopus from database inception to November 2021. Randomized clinical trials (RCTs) with at least two intervention arms with either OC, metformin, spironolactone, placebo or any combination of these agents for a minimum of 12 weeks were included. No language or date restrictions were applied. We performed a frequentist random effects network meta-analysis to estimate mean differences (MDs) and standardized mean differences (SMDs) alongside 95% confidence…
How strong is the evidence?
Evidence Hub reads this as a meta-analysis, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid. Reported size: 6,837 participants or records.
Read the paper
Related studies
- Increased expression of circulating miRNA-93 in women with polycystic ovary syndrome may represent a novel, non-invasive biomarker for diagnosis
- Identification of key genes associated with polycystic ovary syndrome (PCOS) and ovarian cancer using an integrated bioinformatics analysis
- Identification of key pathways and genes in polycystic ovary syndrome via integrated bioinformatics analysis and prediction of small therapeutic molecules
- Regulation of Androgen Receptor Expression Alters AMPK Phosphorylation in the Endometrium: In Vivo and In Vitro Studies in Women with Polycystic Ovary Syndrome
- Effect of oral administration of low-dose follicle stimulating hormone on hyperandrogenized mice as a model of polycystic ovary syndrome
- Systems pharmacology to investigate the interaction of berberine and other drugs in treating polycystic ovary syndrome
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.